What is the role of medications in the treatment of pulmonary alveolar proteinosis (PAP)?

Updated: Dec 18, 2019
  • Author: Roger B Olade, MD, MPH; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Granulocyte-macrophage colony-stimulating factor (GM-CSF) may be useful in approximately 50% of patients with acquired disease, although it is still regarded as experimental. (Adequate dosing schedules are under investigation.) GM-CSF is unsuccessful in congenital disease.

With solitary pulmonary opacities, not treating and observing the natural history of the disease is appropriate. It often resolves over 3-9 months.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!